Page 97 - MemoriaES-Eng

www.ciberes.org

• B di, k M, l Zl, J VJ, F k, g d .. CTNNA3
Most relevant ernSteinASHonuMMuSoHnSonluHArtYAutrinet Al
(α-catenin) gene variants are associated with diisocyanate asthma: a replication
scientific study in a Caucasian worker population. Toxicol Sci. 2013 Jan;131(1):242-6.

articles
• SAStre B, FernándeZ-nieto M, rodrígueZ-nieto MJ, AguAdo e, SAStre J, del PoZo V. Distinc-
tive bronchial inflammation status in athletes: basophils, a new player. Eur J Appl

Physiol. 2013 Mar;113(3):703-11.

• SirAcuSA A, de BlAY F, Folletti i, MoScAto g, oliVieri M, Quirce S et Al.. Asthma and expo-
sure to cleaning products - a European Academy of Allergy and Clinical Immunology

task force consensus statement. Allergy. 2013 Dec;68(12):1532-45.

• VAn kAMPen V, de BlAY F, Folletti i, koBierSki P, MoScAto g, oliVieri M et Al.. Evaluation
of commercial skin prick test solutions for selected occupational allergens. Allergy.

2013;68(5):651-8.

• Aguerri M, cAlZAdA d, MontAner d, MAtA M, Florido F, QuirAlte J et Al.. Differential gene-
expression analysis defines a molecular pattern related to olive pollen allergy. J Biol

Regul Homeost Agents. 2013 Apr-Jun;27(2):337-50.

Bronchial asthma is defined as an inflammatory disease of the airways causing
Highlights
bronchial hyper response and/or airflow obstruction and manifests as symptoms

such as cough, wheezing or breathlessness. Asthma has typically been considered
a disease associated with atopy and/or allergic disease that starts during child-

hood and may or may not persist into adulthood. However, today it is considered
a multifactorial heterogeneous disease that includes different phenotypes, each

with its own natural history and different response to treatment. In this sense, in

addition to allergic or extrinsic asthma and non-allergic or intrinsic asthma, other
phenotypes have been defined over the last two decades based on clinical or

physiological characteristics (seriousness, age of onset, degree of obstruction, re-

sistance to treatment), asthma triggering factors (exercise, allergens, occupation,
asthma induced by aspirin), or type of inflammation (eosinophilic, neutrophilic or

paucicellular). These definitions are based on partial characteristics of the disease,
and although they may be of help, they do not explain the complexity of asthma.

Therefore, today it is necessary to improve asthma phenotype classification, and

there is a knowledge gap in many issues, such as what causes the increase in

asthma, genetic susceptibility and interaction between environmental factors (mi-
crobes, contaminants, etc.) and the immune system, etc. All this means that the

main focus of the asthma CRP is to achieve better asthma classification that allows

new diagnostic and therapeutic approaches and better prediction of the response
to treatment and therapeutic efficacy monitoring.

To do this, the asthma CRP consists of a primarily translational work group incor-

porating basic research and clinical knowledge as fundamental pillars. The asthma 13
CRP aspires to be a national and international leader in understanding asthma, 20
T
moving forward in learning about new diagnostic markers as well as possible OR
P
therapeutic targets which, when monitored, allow evaluating patient recovery. The RE
asthma CRP is therefore taking another step closer to personalized medicine for L
A
the treatment of asthma.
NU
N
A
S /
E
ER
B
CI

97